On November 5, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported that it will host a live conference call on Tuesday, November 6, 2018 at 8:30 a.m. ET (Press release, OncoSec Medical, NOV 5, 2018, https://ir.oncosec.com/news/detail/1965/oncosec-to-host-conference-call-to-review-preliminary-keynote-695-data [SID1234530729]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the conference call, OncoSec’s leadership will review preliminary clinical and immunological data from its ongoing registration-directed KEYNOTE-695 study. KEYNOTE-695 is a global, multicenter, registration-directed Phase 2b trial of TAVO (intratumoral tavokinogene telseplasmid/IL-12) in combination with intravenous pembrolizumab (KEYTRUDA), in patients with Stage III/IV metastatic melanoma who have definitively failed FDA approved anti-PD-1 treatments, pembrolizumab and/or nivolumab (OPDIVO).
The conference call will be accessible by dialing 1-844-562-3893 (domestic) or 1-409-220-9946 (international) and referring to conference ID 7767858. An accompanying presentation will be referenced during the conference call and can be accessed under "Events and Presentations" in the Investors section of OncoSec’s website at ir.oncosec.com. A replay of the webcast will be available shortly after the conference call and will be available for 30 days following the call.
Data from KEYNOTE-695 will also be presented at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting taking place on November 7-11, 2018 in Washington, D.C.